{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T22:24:05Z","timestamp":1782080645831,"version":"3.54.5"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T00:00:00Z","timestamp":1614816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T00:00:00Z","timestamp":1614816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["TL1 TR002380"],"award-info":[{"award-number":["TL1 TR002380"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["K23AI143882"],"award-info":[{"award-number":["K23AI143882"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s00520-021-06106-y","type":"journal-article","created":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T05:02:57Z","timestamp":1614834177000},"page":"5293-5301","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Early, empiric high-dose leucovorin rescue in lymphoma patients treated with sequential doses of high-dose methotrexate"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2146-5766","authenticated-orcid":false,"given":"Jason N.","family":"Barreto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen T.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin F.","family":"Barreto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin C.","family":"Mara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross A.","family":"Dierkhising","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Witzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie A.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,4]]},"reference":[{"key":"6106_CR1","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1056\/NEJM198303033080902","volume":"308","author":"AI Freeman","year":"1983","unstructured":"Freeman AI, Weinberg V, Brecher ML, Jones B, Glicksman AS, Sinks LF, Weil M, Pleuss H, Hananian J, Burgert EO Jr, Gilchrist GS, Necheles T, Harris M, Kung F, Patterson RB, Maurer H, Leventhal B, Chevalier L, Forman E, Holland JF (1983) Comparison of intermediate-dose methotrexate with cranial irradiation for the post-induction treatment of acute lymphocytic leukemia in children. N Engl J Med 308:477\u2013484","journal-title":"N Engl J Med"},{"key":"6106_CR2","unstructured":"Ginsberg SJ, Anderson JR, Gottlieb AJ et al (1987) A randomized trial of high-dose methotrexate versus standard-dose methotrexate following cyclophosphamide, doxorubicin (adriamycin), vincristine, and prednisone with or without bleomycin in the therapy of diffuse large cell lymphoma: preliminary report of Cancer and Leukemia Group B Study 7851. NCI Monogr:77\u201380"},{"key":"6106_CR3","first-page":"489","volume":"15","author":"N Delepine","year":"1995","unstructured":"Delepine N, Delepine G, Cornille H, Brion F, Arnaud P, Desbois JC (1995) Dose escalation with pharmacokinetics monitoring in methotrexate chemotherapy of osteosarcoma. Anticancer Res 15:489\u2013494","journal-title":"Anticancer Res"},{"key":"6106_CR4","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/mpo.2950020313","volume":"2","author":"WH Isacoff","year":"1976","unstructured":"Isacoff WH, Townsend CM, Eiber FR, Forster T, Morton DL, Block JB (1976) High dose methotrexate therapy of solid tumors: observations relating to clinical toxicity. Med Pediatr Oncol 2:319\u2013325","journal-title":"Med Pediatr Oncol"},{"key":"6106_CR5","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/j.1365-2125.2011.04054.x","volume":"73","author":"L Holmboe","year":"2012","unstructured":"Holmboe L, Andersen AM, Morkrid L, Slordal L, Hall KS (2012) High dose methotrexate chemotherapy: pharmacokinetics, folate and toxicity in osteosarcoma patients. Br J Clin Pharmacol 73:106\u2013114","journal-title":"Br J Clin Pharmacol"},{"key":"6106_CR6","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1182\/blood-2013-06-453084","volume":"122","author":"JL Rubenstein","year":"2013","unstructured":"Rubenstein JL, Gupta NK, Mannis GN, Lamarre AK, Treseler P (2013) How I treat CNS lymphomas. Blood 122:2318\u20132330","journal-title":"Blood"},{"key":"6106_CR7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s11864-018-0569-2","volume":"19","author":"R Kansara","year":"2018","unstructured":"Kansara R (2018) Central nervous system prophylaxis strategies in diffuse large B cell lymphoma. Curr Treat Options in Oncol 19:52","journal-title":"Curr Treat Options in Oncol"},{"key":"6106_CR8","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1200\/JCO.1998.16.4.1561","volume":"16","author":"MJ Glantz","year":"1998","unstructured":"Glantz MJ, Cole BF, Recht L, Akerley W, Mills P, Saris S, Hochberg F, Calabresi P, Egorin MJ (1998) High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol 16:1561\u20131567","journal-title":"J Clin Oncol"},{"key":"6106_CR9","first-page":"1039","volume":"50","author":"AT Skarin","year":"1977","unstructured":"Skarin AT, Zuckerman KS, Pitman SW, Rosenthal DS, Moloney W, Frei E 3rd, Canellos GP (1977) High-dose methotrexate with folinic acid in the treatment of advanced non-Hodgkin lymphoma including CNS involvement. Blood 50:1039\u20131047","journal-title":"Blood"},{"key":"6106_CR10","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1200\/JCO.2003.03.036","volume":"21","author":"T Batchelor","year":"2003","unstructured":"Batchelor T, Carson K, O\u2019Neill A, Grossman SA, Alavi J, New P, Hochberg F, Priet R (2003) Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 21:1044\u20131049","journal-title":"J Clin Oncol"},{"key":"6106_CR11","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/S0140-6736(09)61416-1","volume":"374","author":"AJ Ferreri","year":"2009","unstructured":"Ferreri AJ, Reni M, Foppoli M et al (2009) High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 374:1512\u20131520","journal-title":"Lancet"},{"key":"6106_CR12","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1200\/JCO.2012.46.9957","volume":"31","author":"JL Rubenstein","year":"2013","unstructured":"Rubenstein JL, Hsi ED, Johnson JL, Jung SH, Nakashima MO, Grant B, Cheson BD, Kaplan LD (2013) Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol 31:3061\u20133068","journal-title":"J Clin Oncol"},{"key":"6106_CR13","doi-asserted-by":"publisher","first-page":"4283","DOI":"10.1002\/cncr.25278","volume":"116","author":"JS Abramson","year":"2010","unstructured":"Abramson JS, Hellmann M, Barnes JA, Hammerman P, Toomey C, Takvorian T, Muzikansky A, Hochberg EP (2010) Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer 116:4283\u20134290","journal-title":"Cancer"},{"key":"6106_CR14","first-page":"1286","volume":"23","author":"JR Bertino","year":"1963","unstructured":"Bertino JR (1963) The mechanism of action of the folate antagonists in man. Cancer Res 23:1286\u20131306","journal-title":"Cancer Res"},{"key":"6106_CR15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0305-7372(77)80007-8","volume":"4","author":"WA Bleyer","year":"1977","unstructured":"Bleyer WA (1977) Methotrexate: clinical pharmacology, current status and therapeutic guidelines. Cancer Treat Rev 4:87\u2013101","journal-title":"Cancer Treat Rev"},{"key":"6106_CR16","first-page":"709","volume":"61","author":"HM Pinedo","year":"1977","unstructured":"Pinedo HM, Chabner BA (1977) Role of drug concentration, duration of exposure, and endogenous metabolites in determining methotrexate cytotoxicity. Cancer Treat Rep 61:709\u2013715","journal-title":"Cancer Treat Rep"},{"key":"6106_CR17","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.3109\/10428194.2012.676177","volume":"53","author":"M Joerger","year":"2012","unstructured":"Joerger M, Huitema AD, Illerhaus G, Ferreri AJ (2012) Rational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphoma. Leuk Lymphoma 53:1867\u20131875","journal-title":"Leuk Lymphoma"},{"key":"6106_CR18","first-page":"1729","volume":"33","author":"M Levitt","year":"1973","unstructured":"Levitt M, Mosher MB, DeConti RC, Farber LR, Skeel RT, Marsh JC, Mitchell MS, Papac RJ, Thomas ED, Bertino JR (1973) Improved therapeutic index of methotrexate with \u201cleucovorin rescue\u201d. Cancer Res 33:1729\u20131734","journal-title":"Cancer Res"},{"key":"6106_CR19","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1215\/15228517-2008-067","volume":"11","author":"JJ Zhu","year":"2009","unstructured":"Zhu JJ, Gerstner ER, Engler DA, Mrugala MM, Nugent W, Nierenberg K, Hochberg FH, Betensky RA, Batchelor TT (2009) High-dose methotrexate for elderly patients with primary CNS lymphoma. Neuro-Oncology 11:211\u2013215","journal-title":"Neuro-Oncology"},{"key":"6106_CR20","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.3109\/10428194.2013.840780","volume":"55","author":"J May","year":"2014","unstructured":"May J, Carson KR, Butler S, Liu W, Bartlett NL, Wagner-Johnston ND (2014) High incidence of methotrexate associated renal toxicity in patients with lymphoma: a retrospective analysis. Leuk Lymphoma 55:1345\u20131349","journal-title":"Leuk Lymphoma"},{"key":"6106_CR21","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00280-008-0772-0","volume":"63","author":"MR Green","year":"2009","unstructured":"Green MR, Chamberlain MC (2009) Renal dysfunction during and after high-dose methotrexate. Cancer Chemother Pharmacol 63:599\u2013604","journal-title":"Cancer Chemother Pharmacol"},{"key":"6106_CR22","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJM197501092920216","volume":"292","author":"E Frei 3rd","year":"1975","unstructured":"Frei E 3rd, Jaffe NJ, Pitman S (1975) Letter: Limitations of methotrexate and citrovorum-factor treatments. N Engl J Med 292:107\u2013108","journal-title":"N Engl J Med"},{"key":"6106_CR23","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1056\/NEJM197709222971203","volume":"297","author":"RG Stoller","year":"1977","unstructured":"Stoller RG, Hande KR, Jacobs SA, Rosenberg SA, Chabner BA (1977) Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med 297:630\u2013634","journal-title":"N Engl J Med"},{"key":"6106_CR24","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1200\/JCO.1983.1.3.208","volume":"1","author":"HT Abelson","year":"1983","unstructured":"Abelson HT, Fosburg MT, Beardsley GP, Goorin AM, Gorka C, Link M, Link D (1983) Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine. J Clin Oncol 1:208\u2013216","journal-title":"J Clin Oncol"},{"key":"6106_CR25","first-page":"908","volume":"39","author":"RG Stoller","year":"1979","unstructured":"Stoller RG, Kaplan HG, Cummings FJ, Calabresi P (1979) A clinical and pharmacological study of high-dose methotrexate with minimal leucovorin rescue. Cancer Res 39:908\u2013912","journal-title":"Cancer Res"},{"key":"6106_CR26","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1097\/00043426-200403000-00004","volume":"26","author":"IJ Cohen","year":"2004","unstructured":"Cohen IJ (2004) Defining the appropriate dosage of folinic acid after high-dose methotrexate for childhood acute lymphatic leukemia that will prevent neurotoxicity without rescuing malignant cells in the central nervous system. J Pediatr Hematol Oncol 26:156\u2013163","journal-title":"J Pediatr Hematol Oncol"},{"key":"6106_CR27","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s00280-017-3304-y","volume":"79","author":"IJ Cohen","year":"2017","unstructured":"Cohen IJ (2017) Neurotoxicity after high-dose methotrexate (MTX) is adequately explained by insufficient folinic acid rescue. Cancer Chemother Pharmacol 79:1057\u20131065","journal-title":"Cancer Chemother Pharmacol"},{"key":"6106_CR28","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/archinte.1916.00080130010002","volume":"XVII","author":"D Du Bois","year":"1916","unstructured":"Du Bois D, Du Bois EF (1916) Clinical calorimetry: tenth paper a formula to estimate the approximate surface area if height and weight be known. Arch Intern Med XVII:863\u2013871","journal-title":"Arch Intern Med"},{"key":"6106_CR29","doi-asserted-by":"publisher","first-page":"188","DOI":"10.3171\/jns.1994.81.2.0188","volume":"81","author":"J Glass","year":"1994","unstructured":"Glass J, Gruber ML, Cher L, Hochberg FH (1994) Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg 81:188\u2013195","journal-title":"J Neurosurg"},{"issue":"2","key":"6106_CR30","first-page":"1","volume":"2","author":"JA Kellum","year":"2012","unstructured":"Kellum JA, Lameire N, Aspelin P, Barsoum RS, Burdmann EA, Goldstein SL et al (2012) Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney disease: Improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2(2):1\u2013138","journal-title":"Kidney Int Suppl"},{"key":"6106_CR31","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","volume":"21","author":"SC Howard","year":"2016","unstructured":"Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD (2016) Preventing and managing toxicities of high-dose methotrexate. Oncologist 21:1471\u20131482","journal-title":"Oncologist"},{"key":"6106_CR32","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3109\/10428194.2014.927458","volume":"56","author":"S Dalia","year":"2015","unstructured":"Dalia S, Price S, Forsyth P, Sokol L, Jaglal M (2015) What is the optimal dose of high-dose methotrexate in the initial treatment of primary central nervous system lymphoma? Leuk Lymphoma 56:500\u2013502","journal-title":"Leuk Lymphoma"},{"key":"6106_CR33","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1172\/JCI107362","volume":"52","author":"BA Chabner","year":"1973","unstructured":"Chabner BA, Young RC (1973) Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues. J Clin Invest 52:1804\u20131811","journal-title":"J Clin Invest"},{"key":"6106_CR34","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1093\/ndt\/gfu395","volume":"30","author":"D Thomasova","year":"2015","unstructured":"Thomasova D, Anders HJ (2015) Cell cycle control in the kidney. Nephrol Dial Transplant 30:1622\u20131630","journal-title":"Nephrol Dial Transplant"},{"key":"6106_CR35","doi-asserted-by":"publisher","first-page":"714","DOI":"10.2174\/1389200220666190806140844","volume":"20","author":"AK Pannu","year":"2019","unstructured":"Pannu AK (2019) Methotrexate overdose in clinical practice. Curr Drug Metab 20:714\u2013719","journal-title":"Curr Drug Metab"},{"key":"6106_CR36","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1177\/1078155215624262","volume":"23","author":"BR Shank","year":"2017","unstructured":"Shank BR, Seung AH, Kinsman K, Newman MJ, Donehower RC, Burton B (2017) Effects of the leucovorin shortage: pilot study investigating cost, efficacy, and toxicity comparison of low fixed-dose versus body surface area-adjusted leucovorin dosing in patients with resectable colon or metastatic colorectal cancer. J Oncol Pharm Pract 23:163\u2013172","journal-title":"J Oncol Pharm Pract"},{"key":"6106_CR37","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.mehy.2013.08.027","volume":"81","author":"IJ Cohen","year":"2013","unstructured":"Cohen IJ (2013) Challenging the clinical relevance of folinic acid over rescue after high dose methotrexate (HDMTX). Med Hypotheses 81:942\u2013947","journal-title":"Med Hypotheses"},{"key":"6106_CR38","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.mayocp.2019.06.011","volume":"95","author":"S Safadi","year":"2020","unstructured":"Safadi S, Hommos MS, Enders FT, Lieske JC, Kashani KB (2020) Risk factors for acute kidney injury in hospitalized non-critically ill patients: a population-based study. Mayo Clin Proc 95:459\u2013467","journal-title":"Mayo Clin Proc"},{"key":"6106_CR39","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1002\/ijc.31993","volume":"144","author":"YC Cheng","year":"2019","unstructured":"Cheng YC, Nie S, Li L, Li Y, Liu D, Xiong M, Wang L, Ge S, Xu G, on behalf of the EACH study investigators (2019) Epidemiology and outcomes of acute kidney injury in hospitalized cancer patients in China. Int J Cancer 144:2644\u20132650","journal-title":"Int J Cancer"},{"key":"6106_CR40","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1159\/000323740","volume":"33","author":"SY Na","year":"2011","unstructured":"Na SY, Sung JY, Chang JH, Kim S, Lee HH, Park YH, Chung W, Oh KH, Jung JY (2011) Chronic kidney disease in cancer patients: an independent predictor of cancer-specific mortality. Am J Nephrol 33:121\u2013130","journal-title":"Am J Nephrol"},{"key":"6106_CR41","doi-asserted-by":"publisher","first-page":"e9615","DOI":"10.1097\/MD.0000000000009615","volume":"97","author":"M Ubukata","year":"2018","unstructured":"Ubukata M, Hara M, Nishizawa Y, Fujii T, Nitta K, Ohta A (2018) Prevalence and mortality of chronic kidney disease in lymphoma patients: a large retrospective cohort study. Medicine 97:e9615","journal-title":"Medicine"},{"key":"6106_CR42","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2147\/CEOR.S188786","volume":"11","author":"B Demiralp","year":"2019","unstructured":"Demiralp B, Koenig L, Kala J, Feng C, Hamlett EG, Steele-Adjognon M, Ward S (2019) Length of stay, mortality, and readmissions among Medicare cancer patients treated with glucarpidase and conventional care: a retrospective study. Clinicoecon Outcomes Res 11:129\u2013144","journal-title":"Clinicoecon Outcomes Res"},{"key":"6106_CR43","first-page":"779","volume":"61","author":"A Nirenberg","year":"1977","unstructured":"Nirenberg A, Mosende C, Mehta BM, Gisolfi AL, Rosen G (1977) High-dose methotrexate with citrovorum factor rescue: predictive value of serum methotrexate concentrations and corrective measures to avert toxicity. Cancer Treat Rep 61:779\u2013783","journal-title":"Cancer Treat Rep"},{"key":"6106_CR44","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/cpt.729","volume":"102","author":"AS Levey","year":"2017","unstructured":"Levey AS, Inker LA (2017) Assessment of glomerular filtration rate in health and disease: a state of the art review. Clin Pharmacol Ther 102:405\u2013419","journal-title":"Clin Pharmacol Ther"},{"key":"6106_CR45","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/MCC.0b013e32830ef70b","volume":"14","author":"N Lameire","year":"2008","unstructured":"Lameire N, Van Biesen W, Vanholder R (2008) Acute renal problems in the critically ill cancer patient. Curr Opin Crit Care 14:635\u2013646","journal-title":"Curr Opin Crit Care"},{"key":"6106_CR46","first-page":"7169897","volume":"2018","author":"JN Barreto","year":"2018","unstructured":"Barreto JN, McClanahan AL, Rule AD, Thompson CA, Frazee E (2018) Incorporating cystatin C to predict methotrexate elimination in patients with CNS lymphoma and suspicious renal function. Case Rep Hematol 2018:7169897","journal-title":"Case Rep Hematol"},{"key":"6106_CR47","doi-asserted-by":"publisher","first-page":"R25","DOI":"10.1186\/cc12503","volume":"17","author":"K Kashani","year":"2013","unstructured":"Kashani K, Al-Khafaji A, Ardiles T et al (2013) Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care 17:R25","journal-title":"Crit Care"},{"key":"6106_CR48","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1093\/ndt\/gfu292","volume":"29","author":"EA Hoste","year":"2014","unstructured":"Hoste EA, McCullough PA, Kashani K, Chawla LS, Joannidis M, Shaw AD, Feldkamp T, Uettwiller-Geiger DL, McCarthy P, Shi J, Walker MG, Kellum JA, Sapphire Investigators (2014) Derivation and validation of cutoffs for clinical use of cell cycle arrest biomarkers. Nephrol Dial Transplant 29:2054\u20132061","journal-title":"Nephrol Dial Transplant"},{"key":"6106_CR49","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1164\/rccm.201401-0077OC","volume":"189","author":"A Bihorac","year":"2014","unstructured":"Bihorac A, Chawla LS, Shaw AD, al-Khafaji A, Davison DL, DeMuth GE, Fitzgerald R, Gong MN, Graham DD, Gunnerson K, Heung M, Jortani S, Kleerup E, Koyner JL, Krell K, LeTourneau J, Lissauer M, Miner J, Nguyen HB, Ortega LM, Self WH, Sellman R, Shi J, Straseski J, Szalados JE, Wilber ST, Walker MG, Wilson J, Wunderink R, Zimmerman J, Kellum JA (2014) Validation of cell-cycle arrest biomarkers for acute kidney injury using clinical adjudication. Am J Respir Crit Care Med 189:932\u2013939","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06106-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-021-06106-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06106-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,29]],"date-time":"2023-01-29T19:08:58Z","timestamp":1675019338000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-021-06106-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,4]]},"references-count":49,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["6106"],"URL":"https:\/\/doi.org\/10.1007\/s00520-021-06106-y","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,4]]},"assertion":[{"value":"27 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective chart review was approved by the Mayo Clinic Institutional Review Board and performed in accordance with the ethical standards of the 1964 Declaration of Helsinki with adherence to all relevant regulations of the US health insurance portability and accountability act (HIPAA), IRB No. 17-008432, Approved 11 October 2017.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written informed consent or had consent provided for them by their legal power of attorney and were verified through Minnesota Research Authorization prior to data collection.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"E.F.B. provides consultation for FAST Biomedical, unrelated to this work. All other authors declare no potential personal, financial, or ethical conflicts of interest regarding the contents of this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}